FDA Grants ODD to Cevidoplenib for the Treatment of Immune T

FDA Grants ODD to Cevidoplenib for the Treatment of Immune Thrombocytopenia

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

Related Keywords

, Taeyoung Yoon , Oscotec Inc , Patients With Persistent , Chronic Immune Thrombocytopenia , Orphan Drug Designation , Oscotec Announces Topline Results ,

© 2025 Vimarsana